WU, Xiaohua |
FLAMES, NCT04169997: A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 393 | RoW | IMP4927, Placebos | Impact Therapeutics, Inc. | Ovarian Cancer | 02/22 | 12/22 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Active, not recruiting | 3 | 366 | RoW | Olaparib, Matching placebo | AstraZeneca | Ovarian Cancer | 04/25 | 04/26 | | |
|
|
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
CHIPRO, NCT04921527: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 3 | 454 | RoW | chiauranib, CS2164, Placebo, Paclitaxel, Anzatax | Chipscreen Biosciences, Ltd. | Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel | 12/24 | 07/25 | | |
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 440 | RoW | AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo | Akeso | Cervical Cancer | 04/25 | 12/25 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
| Recruiting | 2 | 100 | RoW | IMP4297 | Impact Therapeutics, Inc. | Ovarian Cancer | 03/22 | 08/22 | | |
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 89 | RoW | GLS-010, Full-human anti-pd-1 monoclonal antibodies | Guangzhou Gloria Biosciences Co., Ltd. | Cervical Cancer | 05/22 | 05/23 | | |
|
NCT04836663: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors |
|
|
| Recruiting | 2 | 90 | RoW | TQ-B3525 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | 09/22 | 12/22 | | |
| Recruiting | 2 | 265 | RoW | SHR-1210, Camrelizumab, Famitinib, Famitinib Malate Capsule | Jiangsu HengRui Medicine Co., Ltd. | Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer | 12/22 | 12/22 | | |
NCT05043922: A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma |
|
|
| Recruiting | 2 | 86 | Japan, RoW | CYH33 | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Recurrent Cancer | 06/23 | 06/23 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 03/25 | 10/25 | | |
| Active, not recruiting | 2 | 56 | RoW | SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy, Paclitaxel Injection | Shanghai Shengdi Pharmaceutical Co., Ltd | Locally Advanced Cervical Cancer | 12/24 | 01/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Recruiting | 2 | 70 | RoW | WX390, WXFL10030390 | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 06/24 | 06/24 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
BGB-290-102, NCT03333915: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 128 | RoW | Pamiparib, BGB-290 | BeiGene | Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer | 08/20 | 08/21 | | |
|
|
|
|
|
| Recruiting | 1/2 | 18 | RoW | TC-E202 cells, TCR T Cells, IL-2, Fludarabine, Cyclophosphamide Capsules | TCRCure Biopharma Ltd., Fudan University | Cervical Carcinoma | 12/24 | 08/25 | | |
NCT06682780: A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours |
|
|
| Not yet recruiting | 1/2 | 320 | RoW | LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib, Lenvatinib | LaNova Medicines Limited | Advanced Solid Tumor | 12/27 | 12/29 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
| Not yet recruiting | 1/2 | 208 | RoW | SHR-4375 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Solid Tumors | 05/27 | 05/27 | | |
NCT06770881: JSKN033 in Chinese Subjects with Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1/2 | 430 | NA | JSKN033 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Malignant Tumors | 12/26 | 12/27 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
KUNLUN-001, NCT06375187: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Engineering Tumor Infiltrating Lymphocytes, GC203 TIL | Shanghai Juncell Therapeutics | Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer, Lung Cancer | 11/25 | 05/27 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
| Recruiting | 1 | 20 | RoW | Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection | Fudan University, Cellular Biomedicine Group Ltd. | Cervical Cancer | 07/25 | 07/25 | | |
NCT05952947: HRYZ-T101 Injection for HPV18 Positive Solid Tumor |
|
|
| Recruiting | 1 | 32 | RoW | HRYZ-T101 Injection, Fludarabine + Cyclophosphamide | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva | 12/27 | 02/28 | | |
NCT06001099: PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II |
|
|
| Recruiting | N/A | 2935 | RoW | | Fudan University, Guangzhou Burning Rock Dx Co., Ltd. | Gynecologic Cancer | 06/24 | 12/24 | | |
zheng, zhong |
No trials found |